Sterling Capital Management LLC Decreases Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sterling Capital Management LLC reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 10.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,071,853 shares of the company's stock after selling 237,189 shares during the period. Sterling Capital Management LLC owned about 0.18% of Teva Pharmaceutical Industries worth $45,664,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $29,000. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. IFP Advisors Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its position in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 0.1 %

Shares of TEVA traded down $0.02 during trading hours on Tuesday, hitting $13.59. The stock had a trading volume of 7,201,630 shares, compared to its average volume of 9,908,518. The company's fifty day simple moving average is $15.71 and its 200 day simple moving average is $17.79. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a market cap of $15.40 billion, a P/E ratio of -9.37, a P/E/G ratio of 1.44 and a beta of 0.72.

Remove Ads

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.